Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements

Duperrier, Karine; Eljaafari, Assia; Dezutter‐Dambuyant, Colette; Bardin, Christine; Jacquet, Christine; Yoneda, Koyo; Schmitt, Daniel; Gebuhrer, L.; Rigal, Dominique

doi:10.1016/s0022-1759(00)00147-2

Cited by 98 publications

(81 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, recent data obtained by Ding et al [17] and Decker et al [16] was more comparable to our findings. Different results in the more recent studies may have occurred due to younger DC populations (days 5-7 versus day 8 in the Koller et al study [14]), or maturation effects from the use of fetal bovine serum (FBS) to generate cells [26]. In addition, as shown in this study, a significant portion of patients may have iDC surface CD86 and MHC class II levels that are lower or comparable to those in healthy individuals.…”

Section: Discussionmentioning

confidence: 53%

Altered dendritic cells with tolerizing phenotype in patients with systemic lupus erythematosus

et al. 2008

View full text Add to dashboard Cite

Earlier we showed the generation of tolerizing human monocyte-derived DC following interaction with iC3b-opsonized apoptotic cells. In this study we examine the generation of DC with our previously described tolerogenic phenotype in patients with the systemic autoimmune disease systemic lupus erythematosus (SLE). Monocyte-derived DC were generated in 71 SLE patients, characterized, and then tested for clearance of iC3b-opsonized 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethyl-indocarbocyanineperchlorate-stained apoptotic cells using flow cytometry, and for autologous T-cell activation using autologous mixed lymphocyte reaction (AMLR), at the same time as controls. Compared with healthy, ageand gender-matched controls, SLE patients showed upregulation of MHC class II, with a mean expression of 130.5%736.8% (po0.007); CD86 in immature DC from SLE patients, generated in autologous human or control plasma, were also upregulated, with mean expression 106.6%718.0% (po0.03). A significant (420%) reduction in iC3b-apoptotic cell uptake, together with increased autologous mixed lymphocyte reaction, was seen in 75% of SLE patients. Mean 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethyl-indocarbocyanineperchloratestained apoptotic cell acquisition was 70.0%724% (po0.0001) compared with healthy controls. Altered generation of a tolerizing DC phenotype was seen in at least one third of SLE patients following interaction with iC3b-opsonized apoptotic cells. These results suggest that a substantial portion of SLE patients fail to generate DC with a tolerizing phenotype.

show abstract

Section: Discussionmentioning

confidence: 53%

Altered dendritic cells with tolerizing phenotype in patients with systemic lupus erythematosus

et al. 2008

View full text Add to dashboard Cite

show abstract

“…However, the additional effect on GO sensitivity of IFN-g treatment in the presence of GM-CSF (Figure 6b) could not be explained by the fraction of activated cells (Figure 6a). IFN-g treatment of GM-CSF-treated cells additionally increased endocytic capacity as measured by dextran-FITC uptake, 25 possibly reflecting the increased capacity of these cells to CD33 independently take up GO (Figure 7c). Also, the ability of AML-193 cells to CD33 specifically internalize GO and the capacity to renew the expression of empty CD33 molecules on the cell surface correlated with the activation status of the cells.…”

Section: Discussionmentioning

confidence: 93%

“…25 Briefly, 2 Â 10 5 cells were resuspended in culture medium and cultured for 15 min at 371C. Subsequently, 1 mg/ml dextran-FITC (Polysciences Inc., Warrington, PA, USA) was added and samples were incubated for 2 h at 371C.…”

Section: Dextran-fitc Analysis Of Endocytic Capacitymentioning

confidence: 99%

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

et al. 2003

View full text Add to dashboard Cite

Multicenter phase II trials with Gemtuzumab Ozogamicin (GO/ Mylotarg s ), consisting of a CD33 antibody linked to the cytotoxic drug calicheamicin, have shown a 30% overall response rate in relapsed acute myeloid leukemia patients. However, no clear correlation was observed between CD33 expression on leukemic blasts and response to GO therapy. We analyzed the CD33 specificity of GO-induced cell death and the effect of GO on CD33-negative malignancies. We demonstrate that lysis induced by clinically relevant GO concentrations is partially CD33 mediated, and that efficient non-CD33-mediated GO uptake can occur via endocytosis. In agreement with these results, we observed GO-mediated death of human CD33-negative acute lymphoblastic leukemia cells both in vitro and in vivo in an NOD/SCID mouse model. Finally, sensitivity to GOinduced cell death was at least partially determined by the activation status of leukemic cells, with cells in activated phases of the cell cycle being most effective in both CD33-specific GO internalization, renewed expression of CD33 molecules, and non-CD33-mediated GO uptake via endocytosis. In conclusion, these data provide mechanistic insight into the efficacy of GO in CD33-positive as well as in CD33-negative malignancies with endocytic capacity, and provide a rationale for the use of GO in the treatment of malignancies with endocytic capacity.

show abstract

“…The phagocytic activity of macrophages was measured according to a previously described method with slight modifications (Duperrier et al, 2000). After pre-incubation for 48 h, macrophages (2 × 10 6 cells/well) were treated with varying concentrations of PFIO (from 50 to 500 μg/ml) at 37°C for 6 h. Cells were resuspended in 1 ml of PBS containing 1% human Ab serum with FITC-labeled dextran (1 mg/ml) and incubated at 37°C for 30 min.…”

Section: Determination Of Phagocytic Uptakementioning

confidence: 99%

Immunostimulating Activity by Polysaccharides Isolated from Fruiting Body of Inonotus obliquus

Won

Lee

Kwon

et al. 2011

Molecules and Cells

View full text Add to dashboard Cite

In this study, we investigated the immunostimulating activity of polysaccharides isolated from fruiting body of Inonotus obliquus (PFIO). Additionally, the signaling pathway of PFIO-mediated macrophage activation was investigated in RAW264.7 macrophage cells. We found that PFIO was capable of promoting NO/ROS production, TNF-α secretion and phagocytic uptake in macrophages, as well as cell proliferation, comitogenic effect and IFN-γ/IL-4 secretion in mouse splenocytes. PFIO was able to induce the phosphorylation of three MAPKs as well as the nuclear translocation of NF-κB, resulting in activation of RAW264.7 macrophages. PFIO also induced the inhibition of TNF-α secretion by anti-TLR2 mAb, consequently, PFIO might be involved in TNF-α secretion via the TLR2 receptor. In addition, our results showed that oral administration of PFIO suppressed in vivo growth of melanoma tumor in tumorbearing mice. In conclusion, our experiments presented that PFIO effectively promotes macrophage activation through the MAPK and NF-κB signaling pathways, suggesting that PFIO may potentially regulate the immune response.

show abstract

Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements

Cited by 98 publications

References 25 publications

Altered dendritic cells with tolerizing phenotype in patients with systemic lupus erythematosus

Altered dendritic cells with tolerizing phenotype in patients with systemic lupus erythematosus

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

Immunostimulating Activity by Polysaccharides Isolated from Fruiting Body of Inonotus obliquus

Contact Info

Product

Resources

About